Skip to main content
Journal cover image

Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective.

Publication ,  Journal Article
Tsilimigras, DI; Ntanasis-Stathopoulos, I; Moris, D; Spartalis, E; Pawlik, TM
Published in: Surgical oncology
December 2018

Hepatocellular carcinoma (HCC) is a major contributor to the global cancer burden. Given the current limited options to treat advanced HCC, understanding the molecular basis of HCC carcinogenesis and pinpointing druggable targets will be important to identify future HCC treatments. Epigenetic modification by inhibiting histone deacetylases (HDAC) is an emerging approach with promising results in cancer treatment. In the preclinical setting, HDAC inhibitors such as valproic acid sodium, panobinostat, vorinostat, trichostatin A, sodium butyrate, belinostat and romidepsin have demonstrated antitumor efficacy via activation of classic and alternative cell death molecular cascades. Combination regimens with the tyrosine kinase inhibitor sorafenib, poly(ADP-ribose) polymerases, proteasome and mammalian target of rapamycin inhibitors have shown promise. Phase I/II clinical studies with belinostat monotherapy and the combination of resminostat with sorafenib have suggested response and survival benefits. The safety profile was favorable with manageable adverse events and a low incidence of grade 3/4 toxicity. We herein review the role and potential therapeutic impact of epigenetic regulation through histone deacetylase inhibitors (HDACi) in the treatment of HCC.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Surgical oncology

DOI

EISSN

1879-3320

ISSN

0960-7404

Publication Date

December 2018

Volume

27

Issue

4

Start / End Page

611 / 618

Related Subject Headings

  • Prognosis
  • Oncology & Carcinogenesis
  • Liver Neoplasms
  • Humans
  • Histone Deacetylase Inhibitors
  • Carcinoma, Hepatocellular
  • Animals
  • 3211 Oncology and carcinogenesis
  • 3203 Dentistry
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tsilimigras, D. I., Ntanasis-Stathopoulos, I., Moris, D., Spartalis, E., & Pawlik, T. M. (2018). Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective. Surgical Oncology, 27(4), 611–618. https://doi.org/10.1016/j.suronc.2018.07.015
Tsilimigras, Diamantis I., Ioannis Ntanasis-Stathopoulos, Demetrios Moris, Eleftherios Spartalis, and Timothy M. Pawlik. “Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective.Surgical Oncology 27, no. 4 (December 2018): 611–18. https://doi.org/10.1016/j.suronc.2018.07.015.
Tsilimigras DI, Ntanasis-Stathopoulos I, Moris D, Spartalis E, Pawlik TM. Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective. Surgical oncology. 2018 Dec;27(4):611–8.
Tsilimigras, Diamantis I., et al. “Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective.Surgical Oncology, vol. 27, no. 4, Dec. 2018, pp. 611–18. Epmc, doi:10.1016/j.suronc.2018.07.015.
Tsilimigras DI, Ntanasis-Stathopoulos I, Moris D, Spartalis E, Pawlik TM. Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective. Surgical oncology. 2018 Dec;27(4):611–618.
Journal cover image

Published In

Surgical oncology

DOI

EISSN

1879-3320

ISSN

0960-7404

Publication Date

December 2018

Volume

27

Issue

4

Start / End Page

611 / 618

Related Subject Headings

  • Prognosis
  • Oncology & Carcinogenesis
  • Liver Neoplasms
  • Humans
  • Histone Deacetylase Inhibitors
  • Carcinoma, Hepatocellular
  • Animals
  • 3211 Oncology and carcinogenesis
  • 3203 Dentistry
  • 3202 Clinical sciences